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Abstract
Background: The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown.
Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We
evaluated Illumina and 454 for the detection of HIV-1 raltegravir-resistant MVs.
Methods: A5262 was a single-arm study of raltegravir and darunavir/ritonavir in treatment-naı ¨ve patients. Pre-treatment
plasma was obtained from 5 participants with raltegravir resistance at the time of virologic failure. A control library was
created by pooling integrase clones at predefined proportions. Multiplexed sequencing was performed with Illumina and
454 platforms at comparable costs. Illumina sequence analysis was performed with the novel snp-assess tool and 454
sequencing was analyzed with V-Phaser.
Results: Illumina sequencing resulted in significantly higher sequence coverage and a 0.095% limit of detection. Illumina
accurately detected all MVs in the control library at $0.5% and 7/10 MVs expected at 0.1%. 454 sequencing failed to detect
any MVs at 0.1% with 5 false positive calls. For MVs detected in the patient samples by both 454 and Illumina, the
correlation in the detected variant frequencies was high (R
2=0.92, P,0.001). Illumina sequencing detected 2.4-fold greater
nucleotide MVs and 2.9-fold greater amino acid MVs compared to 454. The only raltegravir-resistant MV detected was an
E138K mutation in one participant by Illumina sequencing, but not by 454.
Conclusions: In participants of A5262 with raltegravir resistance at virologic failure, baseline raltegravir-resistant MVs were
rarely detected. At comparable costs to 454 sequencing, Illumina demonstrated greater depth of coverage, increased
sensitivity for detecting HIV MVs, and fewer false positive variant calls.
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Introduction
Current commercial genotypic testing for HIV-1 drug resistance
are based on PCR amplification and population Sanger sequenc-
ing technologies that do not reliably detect the presence of low-
frequency resistance mutations present at ,15–20% of the viral
population [1,2]. These drug-resistant minority variants (MVs) can
significantly increase the risk of antiretroviral treatment (ART)
failure, especially for individuals on non-nucleoside reverse
transcriptase inhibitor (NNRTI)-based regimens [3,4]. Advances
in next-generation sequencing have revolutionized HIV sequenc-
ing and the study of HIV MVs. The most commonly used next-
generation sequencing platforms are those developed by 454/
Roche and Illumina. The general principle behind both of these
technologies lies in the clonal amplification of individual molecules
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synthesis of complementary strands by pyrosequencing (454/
Roche) or through fluorescently labeled nucleotides (Illumina).
The advantage of next-generation sequencing over traditional
Sanger sequencing is the ability to sequence millions of such clonal
sequences in parallel, resulting in significant time and cost savings.
The 454/Roche system historically has been the most popular
platform for HIV applications as it was the first to become
commercially available, has a relatively long read length, and is
supported by a number of available bioinformatics tools. In
contrast, Illumina sequencing offers significantly greater through-
put than 454 and has become the most popular deep sequencing
platform across all applications [5]. However, the lack of well-
validated viral sequence analysis tools for the Illumina platform
remains a hurdle to the wide-spread adoption of Illumina for HIV
applications.
Raltegravir is an integrase strand-transfer inhibitor (INSTI) and
one of the preferred first-line antiretroviral medications for
treatment-naı ¨ve individuals [6]. Resistance to raltegravir shares a
number of characteristics with NNRTI resistance that suggests a
role for raltegravir-resistant MVs in increasing the risk of virologic
failure. For example, single amino acid changes can confer
significant resistance to raltegravir, suggesting a low barrier to
resistance. As with NNRTIs, clinical failure of raltegravir is
commonly accompanied by genotypic evidence of drug resistance
[7]. In addition, virologic failure and emergence of raltegravir
resistance have been reported in a patient with pre-existing
raltegravir-resistant MVs [8]. Despite the detection of primary or
secondary raltegravir-resistant MVs in a subset of patients prior to
raltegravir exposure, evidence is still lacking that these MVs
increase the risk of raltegravir treatment failure [9,10,11].
We compared the performance of Illumina and 454 in the
detection of HIV-1 MVs in a control library and from pre-
treatment samples of patients in whom raltegravir-resistant
mutants were detected at the time of virologic failure. The two
main aims of this study are to compare Illumina and 454
sequencing for HIV MV detection and to assess whether
raltegravir-resistant MVs may have contributed to the treatment
failure of patients on a raltegravir-based ART regimen.
Materials and Methods
Patients and Study Design
ACTG A5262 (NCT00830804) was a single-arm study of
raltegravir and darunavir/ritonavir in treatment-naı ¨ve patients
[12]. Patients with more than one darunavir resistance-associated
mutation or with known major integrase resistance-associated
mutations (N155H, Q148H/R/K, Y143C/R, and G140S) were
excluded from the study. Of the 112 participants who initiated
treatment, 5 participants had detectable raltegravir resistance
mutations by population sequencing at the time of virologic
failure. Pre-treatment plasma were obtained from these 5
participants for evaluation of baseline raltegravir-resistant MVs.
All samples had previously measured viral load .100,000 copies/
mL. All participants provided written informed consent and this
study was approved by the Partners institutional review board.
PCR Amplification and Control Library Construction
Stored plasma samples (3 ml) from the five A5262 participants
were ultracentrifuged at 28,0006g for 1 hour to pellet virus prior
to RNA extraction (QIAamp viral RNA minikit). Synthesis of
cDNA was performed using an integrase-specific primer and the
Superscript III reverse transcriptase. A 401 base pair region of the
HIV-1 integrase gene (HXB2 nucleotides 4374–4774) was PCR
amplified using a conserved, nested primer set. Each PCR
amplification step was performed in quadruplicate using PfuUltra
II DNA polymerase. The number of full-length template copy
numbers was estimated after the cDNA synthesis step by using
SYBR green real-time PCR and primers targeting the 59 end of
the region of interest.
The accuracy of the deep sequencing platforms were evaluated
with a control library of clonal HIV sequences mixed at known
concentrations. PCR amplicons from each patient and from the
HXB2 reference strain were inserted into a pCR4-TOPO plasmid
vector (Invitrogen). The HXB2 reference strain and one HIV-1
integrase clone from each patient were selected for PCR
amplification using the high fidelity PfuUltra II DNA polymerase
(Agilent) and T3/T7 primers. The PCR amplicons were gel
purified and quantified by Nanodrop spectrophotometry. A
control library was created by mixing the clones at concentrations
of 60%, 33.4%, 5%, 1%, 0.5%, and 0.1%.
Illumina Deep Sequencing and Sequence Analysis
Illumina library construction and sequencing of the control
library and 5 patient samples were performed at the Partners
Healthcare Center for Personalized Genetic Medicine using the
Illumina HiSeq 2000 platform. The library construction process
was optimized for short amplicon size using an extended DNA
shearing time. The Illumina sequence analysis pipeline (snp-assess)
was created in the Center for Health Bioinformatics at the
Harvard School of Public Health and is publicly available
(https://github.com/hbc/projects/tree/master/snp-assess). Reads
containing undefined nucleotides (’N’s) were filtered out. To avoid
aligning identical reads multiple times remaining FASTQ reads
with identical sequence information were collapsed into unique
representations, using the best base quality information from all
identical reads as base quality for the unique read. Unique reads
were aligned to the consensus reference sequence using NovoAlign
(Novocraft Technologies) with default parameters. Aligned reads
were re-aligned using the GATK framework [13] to minimize
inconsistent and incorrect alignments due to indels. To differen-
tiate low-frequency variations from likely sequencing errors we
described unique reads at each position with their a) quality score
(the Phred score of sequencing quality at a base, assigned by the
sequencer), b) mapping score (the alignment score of a read,
assigned by the Novoalign aligner) and c) k-mer frequency (the
frequency of the 13 bp region surrounding a position). Based on
the outcome of a TopCoder crowdsourcing competition (http://
community.topcoder.com/longcontest/?module=ViewProblem
Statement&compid=24758&rd=15080) [14], we implemented
a random-forest classifier using a combinations of these three
metrics to filter out likely false positive variants before calculating
variant frequency based on the remaining unique reads and their
associated original read counts. The MV limit of detection was
calculated as the threshold that removed 99% of false positive
MVs in the control library. These false positive MVs were
identified at positions where no MVs were expected in the control
library.
A down-sampling analysis was performed using the control
library dataset to determine the assay characteristics at lower
coverage rates by randomly removing unique reads to generate
different coverage depths prior to assessing false positive and
negative variant calls. A total of ten boot-strapping iterations were
performed at each coverage depth to determine the standard
deviations.
The Illumina variant calling algorithm (snp-assess), including
classifiers and training data is available at https://github.com/
hbc/projects/tree/master/snp-assess. A set of scripts providing an
Illumina and 454 Sequencing of HIV-1 Integrase
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using Illumina deep sequencing is available at https://github.
com/hbc/projects/tree/master/jl_hiv along with installation
scripts and dependencies. Illumina sequencing data has been
deposited in the European Nucleotide Archive under study
accession number PRJEB5053 (http://www.ebi.ac.uk/ena/data/
view/PRJEB5053).
454/Roche Deep Sequencing and Sequence Analysis
454 library construction was performed at the Broad Institute of
MIT and Harvard (Cambridge, MA) using the same PCR
amplicon starting product as the Illumina library construction.
Multiplexed sequencing was performed at the Broad Institute
using the GS-FLX platform (approximately the same cost as the
Illumina sequencing run: ,$1200/sample for 454 and ,$800/
sample for Illumina) and at Roche (Branford, CT) on a GS Junior
platform. 454 sequence analysis was performed with V-Phaser,
software designed for rare variant detection in mixed viral
populations [15]. For the cross-platform comparisons, V-Phaser
variant calls below the Illumina limit of detection were excluded
from the analysis.
In brief, reads for each sample were aligned to a portion the
HXB2 reference genome (K03455.1) from position 3596 to 3996
using Mosaik (version 1.0.1388, github.com/wanpinglee/MO-
SAIK). Alignments outside the amplified region were ignored.
Reads were cleaned of carry-forward and incomplete extension
(CAFIE) and homopolymer/frameshift errors using RC454 [16].
After cleaning, reads were realigned with Mosaik. The alignments
were passed to V-Phaser [15] for variant calling. Briefly, V-Phaser
uses an autocalibration model to recalibrate quality scores for
individual bases. After recalibration it then uses a combined pileup
and two-site phasing model to identify positions or pairwise
combinations of positions that have more minor alleles than would
be expected at random accounting for the error probabilities
predicted by the recalibrated base quality. Variant frequencies
were then estimated based on the proportional observations of all
valid alleles at each position, ignoring any reads that presented an
allele at a given position that was not listed as a valid allele in the
initial V-Phaser call set. 454 data is available at: http://trace.ncbi.
nlm.nih.gov/Traces/study/?acc=ERP004411.
Statistical Analysis
Linear regression slopes, 95% confidence intervals, and
goodness of fit (R
2) were calculated and plotted to compare
measured and expected MV frequencies for the control library
and to compare the frequency of MVs detected in the patient
samples across platforms. The false positive rate was calculated by
dividing the number of false positive MV calls by the number of
nucleotides in the amplicon excluding the primer sequences (354
nucleotides). Bland-Altman plots were used to further assess the
level of agreement between platforms by plotting the percent
difference in MV frequencies between Illumina and 454 against
the average of the two measurements.
Results
Illumina and 454 Coverage and Test Characteristics
All 5 patient samples were confirmed to have .100,000 HIV-1
cDNA template copies (range 136,000 to 444,000 copies/mL,
Table S1). The median Illumina coverage of each nucleotide
position was 2.8 million [IQR 1.8–6.2 million] for the five A5262
patient samples and 2.2 million [IQR 1.8–4.2 million] for the
control library. The median 454 coverage for each nucleotide
position was more than 1,000-fold lower: 1349 [IQR 1093–1692]
for the five A5262 patient samples and 2349 [IQR 2348–2350] for
the control library.
The Illumina limit of detection was calculated to be 0.095%,
removing $99% of potential false positives. The VPhaser algorithm
uses position-specific factors to make variant calls and does not
calculate a comparable overall limit of detection for the 454 data.
Illumina sequencing of the control library accurately detected all
nucleotide MVs present at $0.5% and 7 of 10 MVs present at
0.1% (Table 1). One false positive nucleotide MV was detected at
0.2% frequency in the control library (0.3% false positive rate
amongst all 354 nucleotide positions in the amplicon). By contrast,
454 sequencing detected only 8 of 10 MVs present at 1% and 0 of
10 MVs expected to be present at 0.1%. 454 sequencing also had
a significantly higher false positive rate with 5 false positive MVs
detected (1.4% false positive rate) at frequencies ranging from
0.09% to 0.6%. Similar results were obtained when analyzing the
data at the amino acid level (Table 2). Illumina detected all
expected amino acid MVs with the exception of 1 of 4 MVs
expected at 0.1%. On the other hand, 454 failed to detect 1 of 2
amino acid MVs present at 1% and all 4 of the MVs expected at
0.1%. The numbers of false positive MVs calls remained
unchanged from the nucleotide analysis.
In addition, the frequencies of the MVs detected by Illumina
were significantly closer to the expected frequencies when
compared to the frequencies detected by 454 sequencing
(nucleotide: Illumina slope =1.08 [95% CI 1.03–1.11] vs. 454
slope 0.75 [95% CI 0.74–0.76]; amino acid: Illumina slope =0.89
[95% CI 0.78–1.0] vs. 454 slope 0.74 [95% CI 0.71–0.77];
Figure 1).
A5262 Patient Samples
Illumina sequencing detected 2.4-fold more nucleotide MVs
and 2.9-fold more amino acid MVs compared to 454 sequencing
(Figure 2a and 2c, Illumina vs. 454: 477 vs. 197 for nucleotide
MVs and 153 vs. 53 amino acid MVs, respectively). The MVs
detected by both Illumina and 454 were present at higher
frequencies than those detected by only a single platform. The
frequencies of MVs detected by both 454 and Illumina in the 5
patient samples were highly correlated (nucleotide: R
2=0.92,
P,0.001, N=163; amino acid: R
2=0.89, P,0.001; Figure 2b
and 2d, respectively). At the lower MV frequencies, the Bland-
Altman plot showed that 454 tended to report higher frequencies
compared to Illumina, especially for the amino acid analysis
(Figure S1). We also manually inspected nine nucleotide positions
where MVs were detected for at least one patient at relatively high
frequency (.1%) by 454, but not by Illumina sequencing. All of
these sites were either adjacent to homopolymers or had evidence
of strand bias that were indicative of artifact.
The only raltegravir-resistant MV detected was an E138K
mutation detected at a frequency of 0.15% in one participant by
Illumina sequencing, but not by 454. This mutation was not
detected by standard genotyping at the time of virologic failure.
Down-sampling Illumina Sequence Coverage and
Increasing 454 Coverage
The effect of down-sampling the Illumina coverage level was
performed by 10 iterations of random sampling from all control
library reads to generate the varying coverage depth. This analysis
showed that the true positive and false positive rates remained
relatively constant down to 60,0006coverage, which implies that
,10% of the observed nucleotide coverage was needed to produce
similar Illumina assay characteristics (Figure 3).
For one of the A5262 patient libraries, we repeated the 454
sequencing at a much higher read coverage. The median coverage
Illumina and 454 Sequencing of HIV-1 Integrase
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run to 6384 on the repeat. We found a 2-fold increase the number
of nucleotide MVs (from 49 to 98). The number of MVs detected
by both Illumina and 454 increased from 38 to 57, resulting in far
fewer nucleotide MVs detected by Illumina alone (64 MVs in run
1 vs. 45 MVs in run 2). When a similarly increased 454 coverage
was used to detect MVs in the control library, the number of 0.1%
MVs detected increased from 0 to 6 out of the 10 expected
positions. However, the number of false positive MVs reported by
V-Phaser also increased substantially (1.4% to 8.5% false positive
rate).
Discussion
This study had two main goals: to compare the Illumina and
454/Roche platforms for HIV deep sequencing and to evaluate
the presence of raltegravir-resistant HIV-1 MVs in participants of
ACTG A5262 in whom raltegravir resistance mutations were
detected by standard population sequencing at the time of
virologic failure. Using a novel Illumina sequence analysis pipeline
(snp-assess), we found that at comparable cost, Illumina provided
.1,0006 greater nucleotide coverage compared to 454 as
analyzed by the V-Phaser software. In addition, Illumina sequenc-
ing provided increased sensitivity for detecting HIV MVs and
reported fewer false positive variants than did 454 sequencing. A
down-sampling analysis showed that similar rates of Illumina false
positive and false negative MV detection could be achieved with
,10% of the nucleotide coverage rates used in the current study.
This finding suggests that significantly more samples can be
multiplexed on an Illumina flow cell without sacrificing accuracy,
dramatically enhancing the cost-savings available with Illumina
sequencing compared to 454. Increasing the depth of coverage by
454 improved MV detection in the patient samples, but at
significantly higher cost.
One of the hurdles to the wide-spread adoption of Illumina
sequencing has been the need to validate Illumina viral sequencing
and sequencing analysis pipelines against those available for the
more established 454 platform. For that reason, we decided to
compare Illumina sequencing results against 454 sequencing and
the V-Phaser sequence analysis algorithm. V-Phaser is a variant
calling package that uses both phase information and base quality
to optimize the accuracy of variant calls for highly diverse viral
genomes. It achieves .97% sensitivity and specificity and
compares favorably to other commonly-used 454 viral variant
callers [15]. The results of this study support the findings of the few
previous reported comparisons of Illumina and 454 for HIV
sequencing. One study used a clonal control library to compare
the ability of Illumina and 454 sequencing to estimate viral
diversity estimation and perform haplotype reconstruction. That
study found higher accuracy and throughput with Illumina, but
advantages with 454 in haplotype reconstruction [17]. A second
study compared four different deep sequencing platforms to
predict HIV-1 coreceptor tropism [18]. Compared to 454,
Illumina had similar rates of substitution errors, but 20-fold lower
deletion errors. A few reports have compared Illumina and 454 for
the sequencing of bacterial and non-HIV viral genomes [19,20].
In those studies, the two platforms showed excellent concordance
in detected variant frequencies, but Illumina demonstrated fewer
insertions/deletions and significant cost savings.
The direct comparison of next generation sequencing platforms
can be challenging given differences in sample preparation and
analysis. Unlike some of the previously described studies, we
Table 1. Performance of Illumina and 454 sequencing for the detection of nucleotide minority variants within the control library.
Expected Variant % N Median Variant % by Illumina Missed by Illumina (FN) Median Variant % by 454 Missed by 454 (FN)
100% 299 100% 0 100% 0
40 2 55.2 0 32.0 0
39.9 1 32.4 0 31.7 0
39.5 1 44.4 0 31.1 0
38.9 1 44.5 0 31.0 0
38.4 2 47.2 0 30.3 0
34.4 2 37.9 0 26.2 0
34 1 30.0 0 25.6 0
33.5 1 29.1 0 25.1 0
33.4 8 30.2 0 25.2 0
6.6 1 8.2 0 6.9 0
6.1 1 7.8 0 6.4 0
5.1 1 6.1 0 5.3 0
5.0 8 6.1 0 5.3 0
1.0 10 1.4 0 1.2 2
0.6 1 0.6 0 0.5 0
0.5 8 0.5 0 0.5 0
0.1 10 0.2 3 n/a 10
The control library was created by mixing 6 HIV-1 integrase clones at concentrations of 60%, 33.4%, 5%, 1%, 0.5%, and 0.1%. Expected variant percentages include
positions where a MV is present on more than one clone. Median variant % reflects only the minority variants detected by each platform and does not include the
undetected variants. N represents the number of nucleotide positions in the control library where the variant frequency is expected. Illumina detected 1 false positive
minority variant present at 0.2% of the viral population (0.3% false positive rate) and 454 detected 5 false positive minority variants ranging from 0.09% to 0.6% (1.4%
false positive rate). FN, false negative.
doi:10.1371/journal.pone.0090485.t001
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amplifying the control library and patient HIV sequences by using
one set of conserved primers and PCR reactions. The resulting
amplicons were split into two samples, one used for Illumina and
one for 454 library generation and sequencing. We then adapted
the Illumina library preparation process for processing short
amplicons with excellent resulting sequence coverage. The direct
comparison of next-generation platforms is also complicated by
dramatic intrinsic differences in throughput and read coverage. In
this study, Illumina sequencing produced .1,0006the sequence
coverage of 454 despite similar commercial sequencing costs. We
believe that comparing the sequencing results produced at similar
‘‘real world’’ cost would best reflect the choices available to the
average user. In addition, we performed a down-sampling analysis
showing that Illumina assay characteristics could be replicated
using ,10% of the observed coverage rates. This approach should
allow for increased multiplexing on the Illumina platform without
sacrificing accuracy and significantly decreasing costs.
There are a number of shared characteristics of raltegravir and
NNRTIs that suggests a potential role for drug-resistant MVs in
elevating the risk of virologic failure (e.g., low genetic barrier of
resistance, resistance frequently detected at the time of virologic
failure). However, using two highly sensitive methods of deep
sequencing, we found that raltegravir-resistant MVs were rarely
detected prior to initiating antiretroviral therapy, even in patients
in whom raltegravir resistance mutations were detected at the time
of treatment failure. Whereas one case report showed the
emergence of raltegravir resistance in a patient with baseline
MVs [8], a number of other studies have failed to detect a
significant association between the presence of raltegravir-resistant
MVs and risk of virologic failure [9,10,11,21,22]. However, those
studies were limited by the number of resistance sites that could be
evaluated using mutation-specific assays (e.g., allele-specific PCR)
or by the cost and relatively high limit of variant detection
associated with 454 deep sequencing. With the validation of
Illumina for HIV sequencing, the comprehensive evaluation of
HIV drug-resistant MVs in integrase and other HIV-1 genes
should become increasingly cost-effective and feasible for signif-
icantly larger studies.
This study has a few notable limitations. Assay characteristics
for next-generation sequencing platforms are dependent on the
sequence analysis pipeline. We chose to compare a novel Illumina
pipeline with an existing 454 analysis system (V-Phaser) for several
reasons. First, the Illumina sequence analysis pipeline has not been
optimized to correct for some errors commonly produced in 454
sequencing (e.g., homopolymers and carry-forward/incomplete
extension errors) while the V-Phaser system is not yet able to
Table 2. Performance of Illumina and 454 sequencing for the detection of amino acid minority variants within the control library.
Expected Variant % N Median Variant % by Illumina Missed by Illumina (FN) Median Variant % by 454 Missed by 454 (FN)
100% 114 100% 0 100% 0
39.9 1 32.5 0 31.7 0
33.9 1 38.4 0 25.6 0
33.4 1 27.2 0 25.2 0
5.1 1 6.6 0 5.3 0
5.0 6 6.1 0 5.3 0
1.0 2 1.4 0 1.2 1
0.5 1 0.3 0 0.6 0
0.1 4 0.2 1 n/a 4
Expected variant percentages include positions where a MV is present on more than one clone. Median variant % reflects only the minority variants detected by each
platform and does not include the undetected variants. N represents the number of nucleotide positions in the control library where the variant frequency is expected.
Illumina detected 1 false positive minority variant present at 0.7% of the viral population and 454 detected 5 false positive minority variants ranging from 0.09% to
0.6%. FN, false negative.
doi:10.1371/journal.pone.0090485.t002
Figure 1. Measured versus expected minority variant percent-
ages detected in the control library by Illumina and 454
sequencing. (A) Nucleotide percentages are plotted with linear
regression line and 95% confidence intervals. (B) Amino acid
percentages are plotted with 95% confidence intervals. MV, minority
variant.
doi:10.1371/journal.pone.0090485.g001
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constraints in its current implementation. Another challenge in
comparing the results of the two pipelines is that V-Phaser does not
report an overall limit of MV detection as it relies on phasing
between observed variants that is position-specific [15]. For a
more direct comparison of the platforms, we excluded MVs called
by V-Phaser that were below the Illumina limit of detection. While
we found that Illumina has advantages in variant detection, 454
generates significantly longer reads and has advantages in
haplotype reconstruction and linkage analysis that are not part
of the current analysis. While the majority of the 454 sequencing
was performed using the GS FLX system, a subset of the data was
generated with the GS Junior system (e.g., to evaluate the impact
of higher 454 read coverage). The sequencing chemistry is
identical between the two 454/Roche platforms and the perfor-
mance of both instruments has been shown to be nearly identical
as well. Finally, Illumina sequencing of the control library
demonstrated excellent sensitivity of detection, low rate of false
positive variant calls, and high concordance with expected MV
frequencies despite not using additional methods for controlling
for PCR-induced errors such as Primer ID [23]. The use of Primer
ID may have further improved the Illumina error rate, but may be
of greatest benefit in controlling for PCR-induced recombination
events during variant linkage analysis.
Using a novel and now publicly-available sequence analysis
software, we found that Illumina sequencing demonstrates greater
depth of coverage, increased sensitivity for detecting HIV MVs,
and fewer false positive variant calls compared to 454 sequencing
performed at similar costs. In participants of A5262 with
raltegravir resistance at virologic failure, Illumina and 454
sequencing showed that baseline raltegravir-resistant MVs were
rarely detected. Larger studies are needed to evaluate more fully
Figure 2. Minority variants detected by Illumina and/or 454 sequencing in the 5 patient samples combined. (A) Nucleotide minority
variants categorized by platform (Illumina vs. 454) and whether the minority variants were detected by both Illumina and 454 or by one platform
only. The ‘‘Illumina (w/454)’’ category refers to the Illumina minority variant calls that are also detected by 454 and the ‘‘454 (w/Illumina)’’ category
refers to the 454 calls that are also detected by Illumina. (B) Pearson correlation of the nucleotide minority variants detected by both Illumina and 454.
(C) Amino acid minority variants categorized by platform and whether the variants were detected by both Illumina and 454 or by one platform only.
(D) Pearson correlation of the amino acid minority variants detected by both Illumina and 454. MV, minority variant.
doi:10.1371/journal.pone.0090485.g002
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Supporting Information
Figure S1 Bland-Altman analysis of minority variant
frequencies detected by Illumina and 454 deep sequenc-
ing in the 5 patient samples. The y-axis shows the percent
difference in minority variant frequency measurements between
Illumina and 454 results and the x-axis shows the average of the
two measurements for (A) nucleotide and (B) amino acid minority
variant analysis. Only minority variants identified by both
platforms were included in this analysis. Dotted lines represent
95% limits of agreement.
(TIF)
Table S1 Expected plasma HIV-1 RNA viral loads and
measured full-length cDNA template copies used for
deep sequencing library preparation. The viral loads were
previously measured as part of the A5262 study. The number of
full-length template copy numbers used for deep sequencing was
measured after the cDNA synthesis step.
(DOCX)
Table S2 Sequences of the clones used for the control library.
(DOCX)
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